Published in Nat Med on January 23, 2005
P2 receptors in cardiovascular regulation and disease. Purinergic Signal (2007) 1.91
Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol (2012) 1.90
P2Y nucleotide receptors: promise of therapeutic applications. Drug Discov Today (2010) 1.62
A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci U S A (2006) 1.29
What is new in uremic toxicity? Pediatr Nephrol (2008) 1.23
Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal (2008) 1.17
Endothelial dysfunction: a strategic target in the treatment of hypertension? Pflugers Arch (2010) 1.14
Endothelium-dependent contractions: when a good guy turns bad! J Physiol (2008) 1.08
Differential effects of uridine adenosine tetraphosphate on purinoceptors in the rat isolated perfused kidney. Br J Pharmacol (2010) 0.97
P2Y₂ receptor activation decreases blood pressure and increases renal Na⁺ excretion. Am J Physiol Regul Integr Comp Physiol (2011) 0.95
Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. Br J Pharmacol (2009) 0.90
The P2X1 receptor and platelet function. Purinergic Signal (2011) 0.89
Uridine adenosine tetraphosphate is a novel neurogenic P2Y1 receptor activator in the gut. Proc Natl Acad Sci U S A (2014) 0.86
Uridine adenosine tetraphosphate induces contraction and relaxation in rat aorta. Vascul Pharmacol (2008) 0.85
Control of vascular tone by purines and pyrimidines. Br J Pharmacol (2010) 0.85
Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities. Front Immunol (2015) 0.84
Enhanced uridine adenosine tetraphosphate-induced contraction in renal artery from type 2 diabetic Goto-Kakizaki rats due to activated cyclooxygenase/thromboxane receptor axis. Pflugers Arch (2013) 0.84
Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharmacology (2015) 0.83
Diadenosine polyphosphates (Ap3A and Ap4A) behave as alarmones triggering the synthesis of enzymes of the phenylpropanoid pathway in Arabidopsis thaliana. FEBS Open Bio (2011) 0.83
Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes. Br J Pharmacol (2015) 0.82
The "artificial artery" as in vitro perfusion model. PLoS One (2013) 0.82
Uridine adenosine tetraphosphate-induced contraction is increased in renal but not pulmonary arteries from DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol (2011) 0.82
Alterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive rats. Pharmacol Res (2011) 0.80
Towards mRNA with superior translational activity: synthesis and properties of ARCA tetraphosphates with single phosphorothioate modifications. New J Chem (2010) 0.80
The role of uridine adenosine tetraphosphate in the vascular system. Adv Pharmacol Sci (2011) 0.79
Boranophosphate isoster controls P2Y-receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues. J Med Chem (2011) 0.79
Inborn errors of pyrimidine metabolism: clinical update and therapy. J Inherit Metab Dis (2014) 0.79
The touching story of purinergic signaling in epithelial and endothelial cells. Purinergic Signal (2012) 0.76
Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors. Vascul Pharmacol (2015) 0.76
Identification of a potent endothelium-derived angiogenic factor. PLoS One (2013) 0.75
Acute renal failure. Lancet (2005) 5.60
Parent bisphenol A accumulation in the human maternal-fetal-placental unit. Environ Health Perspect (2002) 5.24
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke (2003) 4.63
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
EBPG on Vascular Access. Nephrol Dial Transplant (2007) 3.26
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol (2014) 3.06
Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med (2013) 2.96
Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension (2012) 2.95
The burden of kidney disease: improving global outcomes. Kidney Int (2004) 2.94
Management of crush-related injuries after disasters. N Engl J Med (2006) 2.90
Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol (2009) 2.89
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol (2008) 2.76
EBPG guideline on nutrition. Nephrol Dial Transplant (2007) 2.68
Acute kidney injury: an increasing global concern. Lancet (2013) 2.61
Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant (2012) 2.59
Acute kidney injury. Lancet (2008) 2.44
Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med (2012) 2.38
The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. Nephrol Dial Transplant (2005) 2.38
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest (2004) 2.36
Recommendation for the management of crush victims in mass disasters. Nephrol Dial Transplant (2012) 2.27
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. Nephrol Dial Transplant (2006) 2.17
Noninvasive assessment of local pulse pressure: importance of brachial-to-radial pressure amplification. Hypertension (2005) 2.15
Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. Hypertension (2013) 2.10
Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant (2014) 2.10
Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant (2009) 2.06
The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol (2006) 2.01
Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation (2003) 1.95
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int (2009) 1.93
Chronic kidney disease in adults--UK guidelines for identification, management and referral. Nephrol Dial Transplant (2006) 1.91
EBPG guideline on dialysis strategies. Nephrol Dial Transplant (2007) 1.90
Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol (2012) 1.90
Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2013) 1.90
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int (2004) 1.83
Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol (2007) 1.77
Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis (2007) 1.77
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Oscillometric estimation of central blood pressure: validation of the Mobil-O-Graph in comparison with the SphygmoCor device. Blood Press Monit (2012) 1.74
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*. J Hypertens (2006) 1.74
HIV and AIDS in Bangladesh. J Health Popul Nutr (2008) 1.68
Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney Int (2013) 1.68
Polymorphisms of the beta2 -adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. J Hypertens (2002) 1.68
The personal dialysis capacity test is superior to the peritoneal equilibration test to discriminate inflammation as the cause of fast transport status in peritoneal dialysis patients. Clin J Am Soc Nephrol (2005) 1.67
Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) (2007) 1.67
Transgenic rat model of Huntington's disease. Hum Mol Genet (2003) 1.66
Why less success of the peritoneal dialysis programmes in Europe? Nephrol Dial Transplant (2008) 1.65
EBPG guideline on haemodynamic instability. Nephrol Dial Transplant (2007) 1.65
A bench to bedside view of uremic toxins. J Am Soc Nephrol (2008) 1.63
Effect of the venous catheter site on transpulmonary thermodilution measurement variables. Crit Care Med (2007) 1.63
Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol (2009) 1.62
Adenosine 5'-tetraphosphate is a highly potent purinergic endothelium-derived vasoconstrictor. Circ Res (2008) 1.61
Clinical findings in the renal victims of a catastrophic disaster: the Marmara earthquake. Nephrol Dial Transplant (2002) 1.60
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. Am J Kidney Dis (2004) 1.58
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant (2006) 1.53
Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension (2005) 1.52
Severity of sepsis-induced acute kidney injury in a novel mouse model is age dependent. Crit Care Med (2012) 1.52
Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. J Nephrol (2005) 1.51
Catheter-related blood stream infections (CRBSI): a European view. Nephrol Dial Transplant (2010) 1.50
Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens (2002) 1.50
Defining acute renal failure: RIFLE and beyond. Clin J Am Soc Nephrol (2006) 1.49
Acute central hemodynamic effects of a volume exchange in peritoneal dialysis. Perit Dial Int (2008) 1.49
Therapeutic interventions favorably influencing delayed and slow graft function in kidney transplantation: mission impossible? Transplantation (2008) 1.49
The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transpl Int (2014) 1.48
Characterisation of advanced glycation endproducts in saliva from patients with diabetes mellitus. Biochem Biophys Res Commun (2004) 1.47
Acute renal failure due to crush syndrome during Marmara earthquake. Am J Kidney Dis (2002) 1.47
Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation (2004) 1.46
Small artery elasticity assessed by pulse wave analysis is no measure of endothelial dysfunction. J Hypertens (2007) 1.46
Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. J Hypertens (2003) 1.46
Angiotensinogen promoter haplotypes are associated with blood pressure in untreated hypertensives. J Hypertens (2004) 1.45